uniQure N.V. filed a Form 8-K on September 2, 2026, disclosing the submission of a Biologics License Application to the U.S. FDA for accelerated approval of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, and a concurrent Marketing Authorisation Application to the UK's MHRA for the same therapy.

Key Highlights

  • FDA BLA submitted: uniQure submitted a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of ifezuntirgene inilparvovec (AMT-130) for the treatment of Huntington's disease.
  • UK MAA submitted: The company also submitted a Marketing Authorisation Application to the United Kingdom's Medicines and Healthcare products Regulatory Agency for the same therapy and indication.
  • Therapy name: The candidate is identified in the filing as ifezuntirgene inilparvovec, also referred to as AMT-130.
  • Disclosure date: Both submissions were announced via press release issued September 2, 2026, furnished as Exhibit 99.1 to the filing.
  • Exchange listing: uniQure's ordinary shares, par value €0.05 per share, trade on NASDAQ:QURE on The Nasdaq Global Select Market.

uniQure Files Regulatory Applications in the U.S. and UK for Huntington's Disease Gene Therapy

According to the filing, uniQure N.V. disclosed on September 2, 2026 that it had submitted a Biologics License Application to the United States Food and Drug Administration for the accelerated approval of ifezuntirgene inilparvovec (AMT-130) for the treatment of Huntington's disease. The company simultaneously disclosed a submission of a Marketing Authorisation Application to the United Kingdom's Medicines and Healthcare products Regulatory Agency for the same therapy and the same indication.

The disclosure was made under Item 7.01 (Regulation FD Disclosure) of the Form 8-K. The filing noted that the information, including the accompanying Exhibit 99.1 press release, is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, and is therefore not subject to the liability provisions of that section, unless expressly incorporated by reference in a subsequent filing.

The press release announcing both regulatory submissions was dated September 2, 2026, and attached as Exhibit 99.1. The filing was signed by Jeannette Potts, Chief Legal and Compliance Officer of uniQure N.V., on behalf of the registrant. uniQure is incorporated in The Netherlands, with principal offices at Paasheuvelweg 25a, 1105 BP Amsterdam.

What Was Disclosed

uniQure N.V. reported the submission of regulatory applications for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease to both the U.S. FDA (seeking accelerated approval) and the UK MHRA, announced via a September 2, 2026 press release furnished with the filing.